GSK stops Phase-II lupus trial

Share this article:

The 2012 Galapagos-GlaxoSmithKline alliance has been partly idled. Belgium-based Galapagos announced Monday that GSK has stopped Phase-II exploration of its JAK1 inhibitor GSK2586184 for systemic lupus erythematosus due to lack of effect.

Galapagos said that GSK has put an exploratory half-phase test of this same inhibitor in ulcerative colitis on hold.

Phase-II dosing in a third scenario—psoriasis—has wrapped and the company expects to provide top-line results in the first half of this year. This endpoint means GSK may cough up a milestone payment if results equal proof-of-concept.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.